Suppr超能文献

囊泡谷氨酸转运体抑制剂:结构修饰的亮黄类似物。

Vesicular Glutamate Transporter Inhibitors: Structurally Modified Brilliant Yellow Analogs.

作者信息

Kehrl Jason, Althaus J Christian, Showalter Hollis D, Rudzinski DiAndra M, Sutton Michael A, Ueda Tetsufumi

机构信息

Molecular & Behavioral Neuroscience Institute, Medical School, University of Michigan, 109 Zina Pitcher, Ann Arbor, MI, 48109, USA.

IMS Consulting Group, 485 Lexington Ave, New York, NY, 10017, USA.

出版信息

Neurochem Res. 2017 Jun;42(6):1823-1832. doi: 10.1007/s11064-017-2198-8. Epub 2017 Mar 2.

Abstract

Glutamate uptake into synaptic vesicles in nerve terminals is a pivotal step in glutamate synaptic transmission. Glutamate is the major excitatory neurotransmitter and, as such, the vesicular glutamate transporter (VGLUT) responsible for this uptake is involved in a variety of nervous system functions and various types of pathophysiology. As yet, no VGLUT-specific, membrane-permeable agents have been developed to affect neuronal function in intact neurons, although two potent VGLUTspecific inhibitors are known. These compounds contain diazo and highly charged sulfonic acid groups, rendering them membrane-impermeable and potentially cytotoxic. In an effort to eliminate these undesirable properties, we have developed two novel agents, Brilliant Yellow analogs 1 and 2, which are free of these two groups. We show here that these agents retain highly VGLUT-selective inhibitory activity, despite their reduction in potency, and exhibit no significant cellular toxicity. Potential use of this molecular modification is discussed.

摘要

谷氨酸摄取到神经末梢的突触小泡中是谷氨酸突触传递的关键步骤。谷氨酸是主要的兴奋性神经递质,因此,负责这种摄取的囊泡谷氨酸转运体(VGLUT)参与多种神经系统功能和各类病理生理过程。尽管已知两种有效的VGLUT特异性抑制剂,但尚未开发出影响完整神经元中神经元功能的VGLUT特异性、膜通透性药物。这些化合物含有重氮和高电荷磺酸基团,使其具有膜不可渗透性且可能具有细胞毒性。为了消除这些不良特性,我们开发了两种新型药物,亮黄类似物1和2,它们不含这两个基团。我们在此表明,尽管这些药物的效力有所降低,但仍保留高度VGLUT选择性抑制活性,且未表现出明显的细胞毒性。本文讨论了这种分子修饰的潜在用途。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验